Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Tixagevimab/cilgavimab  COVID-19 treatment studies for Tixagev../c..  C19 studies: Tixagev../c..  Tixagev../c..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 64% Improvement Relative Risk Death/hospitalization/c.. 69% Hospitalization 87% Case 66% c19early.com/tc Young-Xu et al. Tixagev../c.. for COVID-19 Prophylaxis Favors tixagevimab/ci.. Favors control
Young-Xu, 8,087 patient tixagevimab/cilgavimab prophylaxis PSM study: 64% lower mortality [p=0.004], 69% lower combined death/hospitalization/cases [p<0.0001], 87% lower hospitalization [p=0.04], and 66% fewer cases [p=0.03] https://c19p.org/youngxu
copied to clipboard
Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data
Young-Xu et al., medRxiv, doi:10.1101/2022.05.28.22275716 (Preprint)
29 May 2022    Source   PDF   Share   Tweet
PSM retrospective 1,848 immunocompromised patients given tixagevimab/cilgavimab prophylaxis, showing lower mortality, hospitalization, and cases.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2 [Zhou].
risk of death, 64.0% lower, HR 0.36, p = 0.004, treatment 1,733, control 6,354.
risk of death/hospitalization/cases, 69.0% lower, HR 0.31, p < 0.001, treatment 17 of 1,733 (1.0%), control 206 of 6,354 (3.2%), NNT 44.
risk of hospitalization, 87.0% lower, HR 0.13, p = 0.04, treatment 1,733, control 6,354.
risk of case, 66.0% lower, HR 0.34, p = 0.03, treatment 1,733, control 6,354.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Young-Xu et al., 5/29/2022, retrospective, propensity score matching, USA, North America, preprint, 10 authors.
Contact: adit.ginde@cuanschutz.edu.
All Studies   Meta Analysis
This PaperTixagev../c..All
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit